Webinar 2

IBS, SIBO, SIFO GI problems in Diabetes Case discussion

Irritable Bowel Syndrome (IBS)

IBS-DGBI Disorders Of Gut-Brain Interaction

Rome IV Criteria

Recurrent abdominal pain on average at least 1 day/week in the last 3 months, associated with two or more of the following criteria:

- 1. Related to defecation
- 2. Associated with a change in frequency of stool
- 3. Associated with a change in form (appearance) of stool

Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

An overview of important pathophysiological factors in IBS



Algera, Joost, Esther Colomier, and Magnus Simrén. "The dietary management of patients with irritable bowel syndrome: a narrative review of the existing and emerging evidence." *Nutrients* 11.9 (2019): 2162.

Alarming features

Blood in stools

More than 10% unintentional weight loss

Disease that wakes the patient up during the night

Fever

New onset of signs and symptoms after the 50th year of age Indians 45 years?

Family history of colorectal cancer, inflammatory bowel disease, or celiac disease

Hadjivasilis, Alexandros, et al. "New insights into irritable bowel syndrome: from pathophysiology to treatment." *Annals of gastroenterology* 32.6 (2019): 554.

Indian Consensus on IBS in Adults

- Etiopathogenesis of IBS is multi-dimensional including gut-specific mechanisms, altered gut-brain interaction, food intolerance, psychosocial and genetic factors.
- Patients with IBS, particularly those with diarrhea-predominant IBS (IBS-D), are more likely to have SIBO and gut dysbiosis.
- Excessive methane production slows gut transit and is associated with constipation-predominant IBS (IBS-C).
- Gastrointestinal infection with varied pathogens may result in postinfection IBS (PI-IBS)
- COVID-19 may lead to post-COVID-19 IBS
- Probiotics may be helpful but more studies are needed.

Risk factors and pathophysiology of post-infection irritable bowel syndrome (PI-IBS)



CT Cholera Toxin

Ghoshal, U. C., & Rahman, M. M. (2019). Postinfection irritable bowel syndrome in the tropical and subtropical regions: Vibrio cholerae is a new cause of this well-known condition. *Indian Journal of Gastroenterolog y*, 38, 87-94.

Tropical Sprue

- Tropical sprue is a chronic diarrheal disease, possibly of infectious origin, that involves the small intestine and is characterized by malabsorption of nutrients, especially folic acid and vitamin B12.
- Tropical Sprue or post-infectious malabsorption (PI-MAS) has epidemiologic, clinical, and pathophysiological similarities with PI-IBS.

^{1.} Singh, Prashant, and J. Thomas Lamont. "Tropical sprue."

^{2.} Ghoshal, Uday C., et al. "Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology." *Indian Journal of Gastroenterology* (2023): 1-25.

Table 6: Current symptom based management of IBS				
Symptom	First Line	Second Line	Future	
Constipation	Fiber Osmotic laxative including polyethylene glycol Lactulose/Lactitol Stool softner eg, docusate	Bisacodyl	Elobixibat (ileal bile acid transporter inhibitor)	
		Sodium picosulfate		
		Tegaserod (withdrwan)		
		Lubiprostone		
		Linaclotide		
		Prucalopride (5-HT4 agonist)		
Diarrhea	Loperamide	Alosetron		
	Diphenoxylate	Ramosetron		
		Ondasetron		
		Bile acid sequestrant (cholestyramine, cholestipol)		
		Rifaximin		
		Clonidine		
Bloating	Treat constipation	Probiotic		
		Antibiotic (rifaximin)		
Pain		Antispasmodics		
		Anticholinergics		
		Mebeverine		
		Pinnaverium		
		Otilonium bromide		
		Antidepressant		
		Tricyclic anti-depressants		
		• SSRI		
		SNRI		

Ghoshal, Uday C. "Management of Irritable Bowel Syndrome: A Practical Approach."



Fig. 2: Abnormalities in luminal micro-environment in diarrhea-predominant IBS, that are used as therapeutic targets with different pharmacological agents. Abbreviation used: FMT: fecal microbiota transplant (currently in experimental stage)

Algorithm of investigation of patients with irritable bowel syndrome.



Ghoshal, Uday C., et al. "Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology." *Indian Journal of Gastroenterology* (2023): 1-25.

How Are IBS And Small Intestinal Bacterial Overgrowth (SIBO) Related

SIBO is the presence of $\geq 10^3$ colony forming units per millilitre (CFU/mL) of **jejunal aspirate** on culture (or a positive hydrogen lactulose or glucose breath test.)

4-78 % of people with IBS have SIBO

Similar symptoms:

✓Bloating

✓ Abdominal pain

✓Nausea

✓Constipation

✓ Diarrhea

How are IBS and SIBO related

- A positive hydrogen breath test is diagnostic of SIBO, which has been associated with diarrhea-predominant IBS (IBS-D) and IBS with mixed bowel habits (IBS-M).
- A positive methane breath test is indicative of methanogen overgrowth, which has been associated with constipation predominant IBS.

Migrating Motor Complex(MMC) and SIBO

- The feeding phase
- The fasting phase. Housekeeping waves. MMC. Occurs after digestion is complete, every 90-120 minutes. (Small frequent meals?)
- SIBO can increase gut transit time because of gasotransmitters like methane from methane-producing bacteria.

Conditions that may contribute to SIBO

- Scleroderma, diabetes mellitus, hypothyroidism, opioids, Parkinson's disease, multiple sclerosis can reduce gut transit time.
- Medications like PPIs, anticholinergics, antidiarrheals, and tricyclic antidepressants, NSAIDs.

Gasotransmitters

- Hydrogen, methane and hydrogen sulfide.
- IBS-C subjects had higher breath methane that correlated with higher gut microbial diversity and higher relative abundance of stool methanogens, predominantly *Methanobrevibacter*, as well as higher absolute abundance of *Methanobrevibacter smithii* in stool.
- IBS-D subjects had higher breath hydrogen that correlated with lower microbial diversity and higher breath hydrogen sulfide that correlated with hydrogen sulphide-producing bacteria, like *Fusobacterium* and *Desulfovibrio* species.

Methanogens

From SIBO to IMO.

- Intestinal Methanogen Overgrowth (IMO)
- Methanogens in excess in the intestine, not just small bowel.
- Methanogens are archea, not bacteria.

Should you do a breath test?

Breath Test	Treatment	Dosage	Symptoms
Hydrogen	Rifaximin	400 mg three times or 550 mg twice daily for two weeks	Bloating
Hydrogen Sulphide	Rifaximin + Bismuth	Bismuth 524 mg four times a day	Diarrhea, pain, and urgency.
Methane	Rifaximin + Neomycin/ Metronidazole	Neomycin 500 mg twice a day for 14 days. Metronidazole: 250 mg three times a day after food. 10-14 days.	Constipation

Is IBS An Autoimmune Problem?

Post infection IBS

- 1. Antibodies against Cytolethal Distending Toxin B
- 2. Anti Vinculin Antibody

Good to differentiate IBS-D and IBD High Anti-vinculin antibody, more difficult to treat Good to know "it's not all in your head"

Pimentel, Mark, et al. "Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects." *PLoS One* 10.5 (2015): e0126438.

Small Intestinal Fungal Overgrowth (SIFO)

SIFO

- Small intestinal fungal overgrowth (SIFO) is characterized by the presence of excessive number of fungal organisms (mostly Candida) in the small intestine associated with gastrointestinal (GI) symptoms.
- Diagnosed by small bowel aspirate.
- The most common symptoms observed in these patients were belching, bloating, indigestion, nausea, diarrhea and gas.
- Treatment: Fluconazole or nystatin for 2-3 weeks.
- Higher in the immunocompromised and PPI users.
- SIBO and SIFO may be present at the same time.

MAST CELL ACTIVATION SYNDROME (MCAS)

Mast Cell Activation Syndrome (MCAS)

Frequency (%)
57
50
48
40
36
35
30
27
14

 Table 1
 Gastrointestinal symptoms in mast cell activation syndrome

D-4- - 1---4- 1 f...... ... f........... 1

Weinstock, Leonard B., et al. "Mast cell activation syndrome: a primer for the gastroenterologist." *Digestive Diseases and Sciences* 66 (2021): 965-982.

ORGAN AND SYSTEM INVOLVEMENT IN MAST CELL ACTIVATION SYNDROME

Organ/system	Symptom/finding	
Constitutional	Fatigue, fevers, weight loss or gain	
Eyes, ears, nose, throat	Conjunctivitis, tinnitus, hearing loss, rhinitis, sinusitis, sore throat	
Neurologic	Headaches, migraines, brain fog, anxiety, flushing, nausea	
Cardiovascular	Chest pain, palpitations, hypotension	
Urogenital	Frequency, urgency, dysuria	
Esophageal	Heartburn, dysphagia, globus, chest pain	
Stomach	Dyspepsia	
Small and large intestine	Abdominal pain/discomfort, diarrhea, constipation	
Hepatic	Elevated transaminases, hepatomegaly	
Salivary glands	Swelling	
Lymphatics	Lymphadenopathy	
Dermatologic	Flushing, pruritus, urticaria, rashes	
Musculoskeletal	Myalgia, arthralgia, edema	

TREATMENT OF MAST CELL ACTIVATION SYNDROME

Intervention	Timing	Frequency	Examples
Avoidance of known triggers	First line	Daily	Stress, heat, alcohol
Diet interventions	First line	Daily	Low histamine and gluten free
Histamine (H ₁) antagonist	First line	BID	Cetirizine, fexofenadine,
levocetirizine, loratadine			
Histamine (H_2) antagonist	First line	BID	Famotidine, ranitidine, cimeti- dine, nizatidine
Leukotriene receptor antagonist	First line	Daily—BID	Montelukast
Treatment of comorbid conditions	First line	Daily	POTS, EDS
Flavonoid	First line	Daily—BID	Quercetin, luteolin
Mast cell stabilizer	Second line	QID	Cromolyn sodium ^{a, b}
Second-generation H ₁ antagonist	Third line	Daily—BID	Ketotifen ^c
Monoclonal antibody	Fourth line	q4 weeks	Omalizumab ^{d,e}

Weinstock, Leonard B., et al. "Mast cell activation syndrome: a primer for the gastroenterologist." *Digestive Diseases and Sciences* 66 (2021): 965-982.

Diabetes And The Gut



Figure 1 Gastrointestinal complications associated with diabetes.

Sellin, Joseph H., and Eugene B. Chang. "Therapy insight: gastrointestinal complications of diabetes—pathophysiology and management." *Nature clinical practice Gastroenterology & hepatology* 5.3 (2008): 162-171.

Diabetes And The Gut

- 1. Gastroparesis: Delayed gastric emptying.
- Symptoms: nausea, vomiting, reduced appetite, feeling full after eating small amounts of food, abdominal pain, and heartburn, excessive vomiting.
- Damage to vagus nerve.
- 2. Diabetic autonomic neuropathy
- 3. Medications: Metformin, GLP-1 analogues.
- 4. Use of artificial sweeteners.
- 5. Esophageal dysmotility

Why do these changes occur?

- Hypo-and hyper-glycemia
- Autonomic neuropathy
- Not always related to duration of disease
- Enteric myopathy and neuropathy.
- Autoimmune damage
- Metabolic insults that alter critical cellular pathways and essential trophic factor signalling, resulting in smooth muscle atrophy and neural apoptosis
- Possibly trans-differentiation of tissue (i.e. the transformation of one cell type to another).
- Ischemia and hypoxia from microvascular disease of the gastrointestinal tract
- Mitochondrial dysfunction
- Formation of irreversible advanced glycation end products peroxynitrite-mediated endothelial and enteric neuron damage.

Case

Management

- Rule out major disease (Alarm signals)
- Elimination diet. No gluten, no grains
- Low carb food
- Early dinner, TRE.
- Stop snacking
- Sleep
- Correct nutrient depletions
- Rifaximin, Bismuth, Neomycin, Metronidazole, Erythromycin 100 mg
- Probiotics?
- Peppermint Oil
- Melatonin
- Know when to refer

Melatonin in IBS

- Melatonin 6 mg daily (3 mg fasting and 3 mg at bedtime) for 2 months (8 weeks) was compared to placebo.
- Saha, 2007: 3 mg Melatonin at bedtime, small sample size.

^{1.} Faghih Dinevari, M., Jafarzadeh, F., Jabbaripour Sarmadian, A. *et al.* The effect of melatonin on irritable bowel syndrome patients with and without sleep disorders: a randomized double-blinded placebo-controlled trial study. *BMC Gastroenterol* **23**, 135 (2023). <u>https://doi.org/10.1186/s12876-023-02760-0</u>

^{2.} Saha, Lekha, et al. "A preliminary study of melatonin in irritable bowel syndrome." Journal of clinical gastroenterology 41.1 (2007): 29-32.

References

- Cash, Brooks D., Michael S. Epstein, and Syed M. Shah. "A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms." *Digestive diseases and sciences* 61 (2016): 560-571.
- Suarez, Fabrizis L., et al. "Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon." *Gastroenterology* 114.5 (1998): 923-929
- Sellin, Joseph H., and Eugene B. Chang. "Therapy insight: gastrointestinal complications of diabetes—pathophysiology and management." *Nature clinical practice Gastroenterology & hepatology* 5.3 (2008): 162-171.
- Erdogan, Askin, and Satish SC Rao. "Small intestinal fungal overgrowth." *Current gastroenterology reports* 17.4 (2015): 1-7.
- Pimentel, Mark, et al. "Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects." *PLoS One* 10.5 (2015): e0126438.
- Weinstock, Leonard B., et al. "Mast cell activation syndrome: a primer for the gastroenterologist." Digestive Diseases and Sciences 66 (2021): 965-982.
- Book The Microbiome Connection: Your Guide to IBS, SIBO, and Low-Fermentation Eating by Mark Pimentel, Ali Rezaie
- Book The Inside Tract Your Good Gut Guide to Great Digestive Health by Gerard E. Mullin
- https://tmsforacure.org/what-are-mast-cell-diseases/